Uses of Uptaflam

Uptaflam tablets with rapid pain relief are indicated for long-term treatment of chronic arthritis and degenerative joint disease. To ensure the effectiveness when using Uptaflam, users need to follow the instructions of their doctors and refer to the following article for more information about the uses of Uptaflam.

Uptaflam is a brand name drug that contains the active ingredient diclofenac. This is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain and inflammation.
Uptaflam is an ETC drug indicated in: Long-term treatment of chronic arthritis, osteoarthritis, primary dysmenorrhea, juvenile rheumatoid arthritis.

2.1. How to take Uptaflam Medicine Uptaflam is taken orally
2.2. Dosage of the drug Uptaflam Acute pain or primary dysmenorrhea: 2 tablets x 3 times/day. Recurrent pain, recurrent dysmenorrhea: The first dose is 4 tablets, then 2 tablets, 3 times a day. Maximum dose of 8 tablets on the first day, thereafter. 6 tablets/day. Degeneration (damage) joints: 6 tablets/day, divided into 2-3 times. Long-term dose: 4 tablets/day; higher doses should not be used. Rheumatoid arthritis: 6-8 tablets/day, divided into 3-4 times. Maximum total dose is 8 tablets/day. Long-term treatment of rheumatoid arthritis: 4 tablets / day can be increased to 8 tablets / day (if needed), divided into two times. Acute pain (post-traumatic inflammation, swelling) and chronic pain. Ankylosing spondylitis: 1 tablet x 4 times/day, add 1 tablet at bedtime if needed. Juvenile polyarthritis: Children from 1 to 12 years old: 1-3 mg/kg/day, divided into 2-3 times. Handling missed doses: It is still best to take the medicine on time as prescribed by the doctor. Taking the medicine at the right time will ensure the best effect of the medicine. Usually can take medicine 1-2 hours from the time ordered by the doctor, should not make up when the time is too far for the next dose.
Treatment of overdose: Acute diclofenac poisoning manifests mainly as worsening side effects. General measures are to immediately induce vomiting or gastric lavage, activated charcoal can be used to reduce drug absorption in the gastrointestinal tract and in the hepatobiliary cycle.

People with a history of coagulopathy, ulceration, bleeding or perforation of the gastrointestinal tract, patients with renal failure, liver failure, systemic lupus erythematosus, hypertension or heart disease with fluid retention or edema. Infected person. An ophthalmological examination should be performed in patients with visual disturbances while taking diclofenac. Pregnancy: Diclofenac should be used during pregnancy only when clearly needed and only at the lowest necessary dose. The drug should not be used in women planning pregnancy and in the third trimester of pregnancy, because of the risk of inhibiting uterine contractions and premature closure of the ductus arteriosus, causing irreversible increase in urinary pressure, renal failure in the fetus. .
Lactation: Diclofenac is excreted in breast milk sparingly. There are no data on the effects on the nursing infant. Nursing mothers can take diclofenac if non-steroidal anti-inflammatory drugs are required.

Common:
Headache, sink. Epigastric pain, nausea, vomiting, diarrhea, abdominal distension, anorexia, dyspepsia. Increased transaminases. Tinnitus. Uncommon:
Edema, allergies, anaphylaxis including hypotension, rhinitis, urticaria. Abdominal pain, gastrointestinal bleeding, ulceration progression, bloody vomiting, bloody diarrhea, local irritation when placing the drug. Drowsiness, drowsiness, depression, insomnia, anxiety, irritability, excitability. You jute. Bronchospasm. Blurred vision, visual dark spots, eye pain, double vision. Inform your doctor of any unwanted effects encountered while using the drug.

Oral anticoagulants and heparin: Risk of major bleeding.
Quinolone antibiotics: may increase the central nervous system side effects of quinolone antibiotics, leading to convulsions. Aspirin or glucocorticoid: Reduces diclofenac plasma concentrations and increases the risk and severity of gastrointestinal damage.
Diflunisal: Increases diclofenac plasma concentrations and decreases diclofenac clearance which can cause very heavy bleeding in the gastrointestinal tract.
Lithium: Diclofenac may also increase serum lithium concentrations to toxic levels. If concurrent use is required, the patient should be carefully monitored to detect early signs of lithium toxicity and should monitor the blood level of lithium more frequently. The dose of lithium must be adjusted during and after diclofenac treatment.
Digoxin: Diclofenac may increase serum digoxin concentrations and prolong the half-life of digoxin. Blood levels of digoxin should be measured and digoxin dose should be reduced if both drugs are used concurrently. Ticlopidine: increased risk of bleeding.
Hopefully, with the sharing of Uptaflam medicine, it will help the process of using it safely and effectively to treat the disease. If you have any further questions, you should talk to your doctor directly for appropriate indications.